Product Images Effient

This appears to be a table or graph showing the incidence of bleeding events (major or minor) in patients taking Effient and Clopidogrel at various times after randomization. The table also includes the number of patients at risk and the days from randomization.*

This appears to be a chart indicating the percentage of cardiovascular death, nonfatal MI, or nonfatal stroke over a period of 450 days after randomization in patients receiving Clopidogrel for UA/NSTEMI. There are two sets of data, one labeled "Clopidogrel" with percentages of 12.4% and 13.9%, and one labeled "s" with a percentage of 12.4%. The significance of the label "s" is not available.*

This is a table showing various baseline characteristics of patients in a study related to UANSTEMI, including their age, gender, weight, medical history, and other demographic information. There is also a mention of the stent type used and GP lbila nhibitor use. The table displays percentages of events and hazard ratios for Effient and Clopidogrel, indicating which drug was more effective for the patients.*

This appears to be a data table with information on baseline characteristics, percentages, and events related to treatment with two drugs: Effient and Clopidogrel. The data is further broken down by variables such as gender, body weight, region of the world, and previous medical history. The table also includes a comparison of the hazard ratio between the two drugs. Further context and interpretation of the data cannot be determined without additional information.*